11/20 1622  |  Dow  7,553.56    443.7  |  Nasdaq  1,316.12    70.3  |  Russell 2000  385.27    27.1  |  S&P 500  752.44    54.1  |  AMEX  1,157.48    87.9
Dutton Associates Home Page About Dutton Associates Covered Companies Research Alerts Our Analysts Contact Us Email Sign Up
COVERAGE UNIVERSE
 
 
CytoGenix, Inc.
Market Information
Symbol: CYGX
Exchange: BB
Industry: Healthcare, Biotechnology & Pharmaceutical
Analyst
William R. Prather, RPh, MD
Dutton Associates Rating
Speculative Buy
Rating Information
Recent Price: $1.05 (7/2/2006)
Price Target: $1.40
Established: 7/17/2002
Price at Rating: $0.19
Time Frame: 12 Months
Other Information
 
Dutton Associates' Research on CytoGenix, Inc. (PDF format)
3/31/2006 Research Note CytoGenix: First Purchase Order for Their Proprietary Synthetic DNA Termed synDNA Speculative Buy
2/1/2006 Update Report CytoGenix Rating Maintained and Price Target Raised; Our Belief That CytoGenix's Patent Pending synDNA™ Represents Enormous Revenue Potential Speculative Buy
8/29/2005 Update Report CytoGenix Rating Maintained At Speculative Buy; Strategy To Manufacture Highly Purified Plasmid DNA For Customers On An OEM Basis Speculative Buy
4/1/2005 Update Report CytoGenix Inc. Speculative Buy Rating Maintained; Benefiting from Acquisitions and Careful Management Speculative Buy
7/6/2004 Initial Report CytoGenix Rating Maintained At Speculative Buy In Updated Initial Report; A Technology Leader Among The Handful Of Companies Developing Therapeutics Around ODN Technology Speculative Buy
5/4/2004 Research Note CytoGenix's First Therapeutic Product to Move into Human Clinical Studies Speculative Buy
3/8/2004 Research Note CytoGenix Announces Successful Results in Proof-of Concept Pre-clinical Studies in Sepsis Speculative Buy
8/26/2003 Research Note Results of New Anti-Cancer Research Using CytoGenix's ssDNA Technology to be Published Speculative Buy
8/19/2003 Update Report CytoGenix Speculative Buy Rating Maintained In Update Report Speculative Buy
8/12/2003 Research Note Recent Announcements by CytoGenix Indicate Commercial Product Development is on Track Speculative Buy
6/19/2003 Research Note CytoGenix Announces Promising In Vitro Studies; Speculative Buy Maintained Speculative Buy
4/2/2003 Update Report CytoGenix Speculative Buy Rating Maintained Speculative Buy
12/13/2002 Research Note Cytogenix Announces Patent Application For The Treatment Of Herpes Simplex Virus (HSV) Utilizing Its ssDNA Technology Speculative Buy
12/2/2002 Research Note CytoGenix Continues To Advance Commercial Development Of Its Single-Strand DNA Expression Technology Speculative Buy
10/14/2002 Update Report CytoGenix Speculative Buy Rating Reiterated In Update Report Speculative Buy
7/17/2002 Initial Report CytoGenix Speculative Buy Rating Issued In Initial Report Speculative Buy

Current Dutton Associates disclaimer and 17b disclosure information regarding CytoGenix, Inc.

Information, opinions or recommendations contained in Dutton Associates' research reports or research notes are submitted solely for advisory and information purposes. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Such information and the opinions expressed are subject to change without notice. A Dutton Associates research report or note is not intended as an offering or a solicitation of an offer to buy or sell the securities mentioned or discussed. Neither the Firm, its principals, nor the assigned analysts own or trade shares of any company covered. The Firm does not accept any equity compensation. Anyone may enroll a company for research coverage, which currently costs US $35,000 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $47,000 from the Company for 8 Research Reports with coverage commencing on 07/17/2002. Reports are performed on behalf of the public, and are not a service to any company. The analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests and insure independence. Please read full disclosure and other reports and notes on the Company at www.jmdutton.com.

The views expressed in this research report or note accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by Dutton Associates is in any way related to the specific recommendations or views contained in this research report or note.

Dutton Associates. John M. Dutton, President, 4989 Golden Foothill Parkway, Suite 4, El Dorado Hills, CA 95762 Phone (916) 941-8119, Fax (916) 941-8093

Periodic Research Reports and Research Notes on this Company are available at our web site: www.jmdutton.com.

© Copyright 2006, by Dutton Associates